Actelion's share price rises after hedge fund calls on board members to go
This article was originally published in Scrip
Executive Summary
Actelion saw its share rise on the Zurich market on 4 February following the revelation that Elliot Associates, a $17 billion hedge fund, had written to the Swiss biotech's board of directors demanding that certain board members step down. The letter claims that the individuals targeted are acting against shareholders' best interests in resisting a potential takeover. Actelion's share price rose by 3.6% to CHF54.40 after the letter was made public on 3 February.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.